Collegium Pharmaceutical, Inc. (COLL)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$23.53-0.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · COLL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $50 million of the Company’s common stock. The ASR Agreement was undertaken as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Under terms of the ASR Agreement, the Company will pay $50 million to Jefferies LLC and will rece…
Results of Operations and Financial Condition. On August 6, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Executive Vice President and Chief Commercial Officer, Executive Vice President and Chief Medical Officer — Scott Dreyer, Thomas Smith, M.D.: Two senior executives are departing the company.
Completion of Acquisition or Disposition of Assets. As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and together with Commave Seller, the “ Seller Parties ”). On May 12, 2026, pursuant to the Purchase Agreeme…
Results of Operations and Financial Condition. On May 7, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Director — John Fallon, M.D.: Dr. John Fallon is retiring from the Board and will be succeeded by Michael Donovan.
Regulation FD Disclosure. On March 19, 2026, the Company issued a press release announcing that the Company will acquire AZSTARYS® (the “ Press Release ”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also, on March 19, 2026, the Company held a conference call to discuss, among other things, the announcement of the acquisition of AZSTARYS®. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The informatio…
Entry into a Material Definitive Agreement. Equity Purchase Agreement On March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and, together with Commave Seller, the “ Seller Parties ” and each, a “ Seller Party ”). Pursuant to the Purchase A…
Results of Operations and Financial Condition. On February 26, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
of this Current Report on Form 8-K. To the extent that the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 furnished herewith, are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “forecasts,”…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Agreement. On December 23, 2025, Collegium Pharmaceutical, Inc. (the “Company”) entered into a Credit Agreement by and among the Company, the lenders from time to time party thereto and Truist Bank, as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (i) a $580,000,000 term loan, (ii) $300,000,000 of delayed draw term loan commitments, and (iii) a $100,000,000 revolving credit facility. The initial Term Loan was used to repay in full the r…
Termination of a Material Agreement. The information set forth under
Regulation FD Disclosure. On December 30, 2025, the Company issued a press release announcing its entry into the Credit Agreement. The press release is attached hereto as Exhibit 99.2 and is being furnished, not filed, under
Results of Operations and Financial Condition. On November 6, 2025, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Results of Operations and Financial Condition. On August 7, 2025, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Other Information. On July 1, 2025, the Board of Directors of Collegium Pharmaceutical, Inc. (the “Company”) authorized a new share repurchase program to repurchase up to $150 million of the Company’s shares of common stock through December 31, 2026. The timing and amount of any shares purchased on the open market will be determined based on the Company’s evaluation of the market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share re…
The filing discloses the approval of a new Equity Incentive Plan, which is a compensatory arrangement rather than a change in management personnel.
Other Events. On May 12, 2025, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $25 million of the Company’s common stock. The ASR Agreement was undertaken as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Under terms of the ASR Agreement, the Company will pay $25 million to Jefferies LLC and will rece…
Results of Operations and Financial Condition. On May 8, 2025, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Other Events On March 17, 2025, the Company announced the appointment of David Dieter to serve as Executive Vice President and General Counsel, effective March 17, 2025. Mr. Dieter previously served as an independent legal advisor from October 2024 until February 2025 within the biopharma industry. Prior to this, Mr. Dieter served as Vice President, Legal at Horizon Therapeutics USA, Inc. (“Horizon”) (which was acquired by Amgen Inc. in October 2023) where he managed internal and external leg…
Director — Michael Heffernan: The filing discloses the planned retirement of two long-serving directors (including the founder/Chairman) and the nomination of a new director, representing an orderly board refreshment rather than a sudden executive loss.
Results of Operations and Financial Condition. On February 27, 2025, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period and fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
Chief Administrative Officer — Shirley Kuhlmann: The company is losing a senior executive (EVP, CAO, General Counsel) via a termination without cause, which is a significant negative management event.
Director — Nancy Lurker: The filing discloses the appointment of a new independent director to expand the board, which is a routine governance action and not a departure of a senior executive.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.